細胞表面標記物檢測市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190258

細胞表面標記物檢測市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Cell Surface Markers Detection Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內,細胞表面標誌物檢測市場的複合年增長率預計為 8.2%。

預計 COVID-19 大流行將對市場產生重大影響。 細胞表面標記是指附著在細胞膜上的碳水化合物和蛋白質,使細胞表面標記在細胞間信號傳導中發揮重要作用。 許多研究都是利用 COVID-19 抗體與細胞表面標記物之間的相互作用進行的。 例如,2021 年 2 月,發表在 Frontiers in Immunology 上的一篇題為“COVID-19 Impairs Immune Response to Candida Albicans”的研究論文比較了 COVID-19 患者與健康對照者單核細胞上的細胞表面標誌物表達,正在研究中。 他們發現 COVID-19 患者的繼發性真菌感染率增加。 許多 COVID-19 患者的免疫系統較弱,這增加了繼發性真菌感染的發生率。 因此,使用細胞表面標記進行真菌感染研究有望促進市場增長。 這些努力導致了更好地了解疾病和找到治療方法的創新方法。 全球越來越多的此類研究項目正在使用細胞表面標記來研究 COVID-19 的影響。 因此,此類新興市場的發展有望推動市場增長。

推動市場增長的關鍵因素包括對精準醫療的需求不斷增長、診斷的使用不斷增加以及與提高吞吐量和自動化相關的技術進步。 例如,已經鑑定出 200 多種在肺癌中過度表達的細胞表面標誌物,例如細胞角蛋白片段 21-1 和 EGFR 基因突變。 診斷方法用於通過這些標記檢測血液中腫瘤細胞的存在。 全球癌症患者數量的增加預計將對生物標誌物的需求產生積極影響,從而推動細胞表面標誌物檢測市場的增長。 例如,根據 Globocan 2020 報告,2020 年乳腺癌患者總數為 2,261,419 人,其次是肺癌患者(2,206,771 人)和前列腺癌患者(1,414,259 人)。 因此,全球肺部疾病患病率的增加支持了預測期內的市場增長。

精準醫學,也稱為個性化醫學,是根據每個患者的特點量身定制的藥物。 這些藥物指導醫療保健決策,為個體患者提供最有效的治療方法。 由於細胞表面標記充當有助於識別和分類細胞的字母組合,因此在癌細胞表面表達的蛋白質充當特定腫瘤類型的標記。 這種分子鑑定正在推動市場的增長,因為它有助於診斷疾病、尋找疾病的直接治療方法和藥物發現。 許多公司都參與了市場準備,這有望促進市場的增長。 例如,Becton, Dickinson and Company 為研究機構生產 BD Lyoplate 人細胞表面標誌物篩選組合。 它可用於篩選原代細胞、組織和細胞系。 兼容流式細胞術和生物成像技術平台。 面向如此廣泛應用的創新產品有望推動市場增長。

細胞表面標記物檢測的市場趨勢

流式細胞術領域有望增長最快

流式細胞術技術用於識別群體中的不同細胞類型。 在流式細胞術中,單個細胞被高度聚焦的激光照射。 樣品中加入了對感興趣的細胞表面標記物具有特異性的抗體,並允許與細胞相互作用。 該抗體附著在具有發射不同波長光的特性的熒光染料上。 然後它們激發熒光染料,照亮細胞群並捕獲發射的光。 然後可以使用由一系列直方圖和點圖組成的門控策略將細胞分為基於標記的亞群。 細胞表面表達的細胞表面標誌物可以用熒光標記的抗體標記,並通過流式細胞儀分析以確定細胞亞型和功能。

根據2021年9月發表在Star Protocol上的“Flow cytometry detection of surface and intracellular antigens in pancreas from a single mouse embryote”研究,採用流式細胞術檢測了單個胚胎胰腺中的細胞表面蛋白,並進行了定量分析。執行。 同時檢測報告蛋白、細胞表面蛋白和細胞內蛋白,從而在減少所需動物數量的同時發現生物變異體。 這樣,由於上述優點,流式細胞術的細胞檢測有望擴大該領域的市場。

流式細胞術的作用也已擴展到使用細胞表面標記研究免疫系統疾病,包括原發性免疫缺陷。 例如,通過流式細胞術進行的細胞表面染色通常用於研究淋巴細胞克隆性。 T 細胞克隆性研究對於評估與受限 T 細胞相關的原發性免疫缺陷病特別有用。 根據2019年發表在JACI Online上的題為“Flow cytometry: Surface Markers and beyond”的研究,流式細胞術作為一種臨床檢測方法的應用是識別細胞表面標誌物,它已經從鑑定到細胞內蛋白質的表徵,提供多種不同的方法來評估免疫功能以及表徵和診斷免疫疾病。 流式細胞術廣泛用於癌症診斷。 人類發展指數 (HDI) 高的國家在醫療保健方面投入巨資。 因此,這些國家正在進行更多的癌症診斷測試□□並發現更多的癌症病例(國際癌症研究機構,2020 年),這有望推動市場增長。

但是,預計主要市場參與者增加產品發布將推動這一細分市場的發展。 例如,2020 年 6 月,Sysmex America Inc. 宣布推出 XF-1600 流式細胞儀,為實驗室的廣泛應用提供更高的靈活性和效率。

因此,上述所有因素預計將在預測期內推動該細分市場的增長。

北美主導市場,預計在預測期內將保持其份額

北美是最大的細胞表面標記市場。 疾病診斷應用的快速擴展、成熟研究機構的存在以及生物技術行業是推動市場規模的主要因素。 美國目前在北美細胞表面標誌物檢測市場佔據主導地位,預計未來幾年仍將如此。 高醫療保健支出、高技術採用率以及對準確及時診斷的日益關注正在推動美國市場的增長。

美國有許多公司從事該行業,預計該國的需求在預測期內將保持強勁。 總部位於美國的公司包括 Nexcelom Bioscience LLC、Cofactor Genomics Inc.、Abbott Laboratories 和 Beckman Coulter Inc.。 這些公司增加產品發布預計將推動市場增長。 例如,2020年11月,美國研究和臨床診斷公司Bio-Rad Laboratories Inc.推出了三款專為流式細胞儀開發的StarBright Dyes。 這些染料包括 StarBright Blue 700、StarBright Violet 440 和 StarBright Violet 610,它們是與 Bio-Rad 流動抗體結合的熒光納米顆粒,可提供最大亮度和改進的分辨率。 可用於市場檢測中表面蛋白的檢測。 此外,2020 年 10 月,Becton, Dickinson & Company 宣布其集成了 BD FACSDuet 樣品製備系統的 BD FACSLyric 流式細胞儀已獲得美國 FDA 的 510(k) 許可。 主要參與者的此類舉措可能會促進市場的增長。

因此,上述所有因素都有望在預測期內推動市場增長。

細胞表面標誌物檢測市場競爭分析

細胞表面標誌物檢測市場由許多全球參與者組成,尤其是在儀器方面,例如 Becton、Dickinson and Company、Nihon Kohden Corporation、Luminex Corporation、Sysmex Corporation 和 Thermo Fisher Scientific Inc。 然而,一些生物企業活躍於試劑和耗材等利基領域。 目前正在進行進一步整合,參與者主要專注於獲取新技術。 此外,一些主要的市場進入者正專注於收購產品線和品牌。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 擴大在診斷領域的應用
    • 吞吐量和自動化方面的技術進步
    • 對精準醫學的需求不斷增長
  • 市場製約因素
    • 設備成本高
    • 技術複雜性
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(市場規模 - 百萬美元)

  • 產品名稱
    • 流式細胞術
    • 血液分析儀
    • 細胞成像系統
    • 試劑和試劑盒
    • 其他產品
  • 用法
    • 疾病診斷與鑑定
    • 研究和藥物發現
    • 其他用途
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Danaher Corporation(Beckman Coulter Inc.)
    • Becton, Dickinson and Company
    • Bio Rad Laboratories Inc.
    • F. Hoffmann-La Roche Ltd
    • Diasorin SpA(Luminex Corporation)
    • Nihon Kohden Corporation
    • Qiagen NV
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • Grifols SA
    • Nexcelom Bioscience LLC
    • IVD Medical Holding Limited(Immucor Inc.)
    • Agilent Technologies Inc.
    • Sysmex Corporation

第7章 市場機會與今後動向

簡介目錄
Product Code: 66039

The cell surface markers detection market is estimated to register a CAGR of 8.2% during the forecast period, 2022-2027.

The COVID-19 pandemic is expected to have a significant impact on the market. Cell surface markers refer to carbohydrates and proteins that are attached to the cell membrane, allowing cell surface markers to play a crucial role in intercellular signaling. Many research projects are being carried out that involve the interaction of COVID-19 antibodies with cell surface markers. For example, in February 2021, a research article titled 'COVID-19 Impairs Immune Response to Candida Albicans', published in Frontiers in Immunology, studied and compared the cell surface marker expression on the monocytes of COVID-19 patients with healthy controls. The study found an increased rate of fungal co-infections in COVID-19 patients. The rate of secondary fungal infections increases in many COVID-19 patients due to their decreased immunity. Thus, the use of cell surface markers to study fungal infection is expected to boost the market's growth. Such initiatives help drive a better understanding of the disease, leading to innovative ways to find a cure. More such research projects are being conducted worldwide, where cell surface markers are used to study the effect of COVID-19. Thus, such developments are expected to boost the market's growth.

The major factors driving the market's growth include the increasing demand for precision medicine, increased use of diagnostics, and technological advances related to increased throughput and automation. For example, over 200 cell-surface markers have been identified as being overexpressed in lung cancers, including cytokeratin fragment 21-1 and EGFR gene mutation. Diagnostic procedures are used to detect the presence of tumor cells in the blood through these markers. An increase in the number of cancer cases worldwide is expected to positively impact the demand for biomarkers, thus boosting the growth of the cell surface markers detection market. For instance, according to the Globocan 2020 report, the total number of breast cancer cases in 2020 was 2,261,419, followed by lung cancer cases (2,206,771) and prostate cancer cases (1,414,259). Thus, growing prevalence of the lung across across globe supports the market growth over the forecast period.

Precision medicine also known as personalized medicine, is the tailored medication given according to the individual patient's characteristics. These medicines guides healthcare decisions towards a most effective treatment for an individual patient. Since cell surface markers serve as monograms to help identify and classify cells, the proteins expressed on the surface of cancerous cells serve as markers of specific tumor types. This molecule identification helps in disease diagnoses, finding direct treatment for the disease, and drug discovery, thus boosting the market's growth. Many companies are involved in market preparation, which is likely to boost the market's growth. For instance, Becton, Dickinson and Company manufactures the BD Lyoplate Human Cell Surface Marker Screening Panel for research laboratories. It can be used for screening primary cells or tissues and cell lines. It is compatible with flow cytometry and bioimaging technology platforms. Such innovative products with a wide variety of applications are expected to boost the market's growth.

Cell Surface Markers Detection Market Trends

Flow Cytometry Segment is Expected to Grow at the Fastest Rate

The technique of flow cytometry is used to identify different cell types in a population. Single cells are subjected to an intensely focused laser during the procedure. In a sample, interest-related cell surface markers-specific antibodies are added and given time to interact with the cells. Fluorochromes, which have the property of emitting light at various wavelengths, are coupled with these antibodies. The fluorochromes are then excited and the light emitted is captured as the cell population is then passed through a laser. The cells can then be divided into subpopulations based on the markers by using a gating strategy, which consists of a series of histograms and dot plots. Cell surface markers expressed on the cell surface can define cell subtypes and function when they are labeled with fluorescent-labeled antibodies and analyzed by flow cytometry.

According to the study titled "Flow cytometry detection of surface and intracellular antigens in pancreas from a single mouse embryo" published in the Star Protocol in September 2021, Flow cytometry was used to perform a quantitative cell surface protein analysis on a single embryonic pancreas. Detection of reporter, cell surface, and intracellular proteins all at the same time. Allows for the discovery of biological variation while also reducing the number of animals required. Thus, due to above mentned benefits of the flow cytometry in detection of cell, surgace markets anticipated to boost the segment growth.

The role of flow cytometry has broadened to include the study of immune system disorders, including primary immunodeficiency disorders, by using cell surface markers. For instance, cell-surface staining using flow cytometry is often used to investigate lymphocyte clonality. T-cell clonality studies are particularly useful to evaluate primary immunodeficiency disorders associated with a restricted T-cell. According to a study titled 'Flow cytometry: Surface markers and beyond' published in JACI Online in 2019, the application of flow cytometry as a clinical laboratory method evolved from the identification of cell-surface markers to characterizing intracellular proteins and providing multiple different approaches to assess immune function and characterizing and diagnosing immunologic disorders. Flow cytometry is used extensively in diagnosing cancer. Countries with a high Human Development Index (HDI) invest more in healthcare. Thus, more cancer diagnostic tests are conducted, and more cancer cases are detected in these countries (International Agency for Research on Cancer, 2020), which will likely boost the market's growth.

However, increasing product launches by the key market players anticipated to boost the segment. For Instance, In June 2020, Sysmex America Inc. announced the launch of its XF-1600 flow cytometer that provides laboratories with improved flexibility and efficiency for a wide range of applications.

Thus, all above mentioned factors expected to drive the segment growth over the forecast period.

North America Dominates the Market and is Expected to Retain its Market Share During the Forecast Period

The North American region is the largest market for cell surface markers. Rapidly growing applications in disease diagnostics, the presence of well-established research institutions, and the biotech industry are the primary factors behind the large market size. United States currently dominates the cell surface marker detection market in North America, and it is expected to continue its stronghold for a few more years. High healthcare expenditure, a high technological adaptation rate, and an increasing focus on precise and timely diagnostics are driving the market growth in United States.

United States has many companies operating in this sector, owing to which demand from the country is expected to be robust during the forecast period. Some US-based companies in the market include Nexcelom Bioscience LLC, Cofactor Genomics Inc., Abbott Laboratories, and Beckman Coulter Inc. The increased product launches by these players are expected to boost the market growth. For example, in November 2020, Bio-Rad Laboratories Inc., a US-based research and clinical diagnostic company, launched three StarBright Dyes specifically developed for flow cytometry. The dyes include StarBright Blue 700, StarBright Violet 440, and StarBright Violet 610, and they are fluorescent nanoparticles conjugated to Bio-Rad's flow antibodies, providing maximal brightness and improved resolution. They can be used for detecting surface proteins in market detection. Additionally, in October 2020, Becton, Dickinson and Company announced that it received 510(k) clearance from the US FDA for BD FACSLyric Flow Cytometer with the integrated BD FACSDuet Sample Preparation System.Such initiatives by major players are likely to boost the market's growth.

Thus, all aforementioned factors expected to boost the market growth over the forecast period.

Cell Surface Markers Detection Market Competitive Analysis

The cell surface markers detection market consists of many global players, especially on the instrument front, including Becton, Dickinson and Company, Nihon Kohden Corporation, Luminex Corporation, Sysmex Corporation, and Thermo Fisher Scientific Inc. However, several biotech start-ups are active in the reagent, consumables, and other niche fields. There is an ongoing trend of further consolidation, with players mainly focusing on acquiring new technology. Some key market participants are also focusing on acquiring product lines and brands.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Use in Diagnostics
    • 4.2.2 Technological Advances Related to Increased Throughput and Automation
    • 4.2.3 Increasing Demand for Precision Medicine
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Complexity of Techniques
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 Product
    • 5.1.1 Flow Cytometry
    • 5.1.2 Hematology Analyzers
    • 5.1.3 Cell Imaging Systems
    • 5.1.4 Reagents and Kits
    • 5.1.5 Other Products
  • 5.2 Application
    • 5.2.1 Disease Diagnosis and Identification
    • 5.2.2 Research and Drug Discovery
    • 5.2.3 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Bio Rad Laboratories Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Diasorin SpA (Luminex Corporation)
    • 6.1.7 Nihon Kohden Corporation
    • 6.1.8 Qiagen NV
    • 6.1.9 Siemens Healthineers
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Grifols SA
    • 6.1.12 Nexcelom Bioscience LLC
    • 6.1.13 IVD Medical Holding Limited (Immucor Inc.)
    • 6.1.14 Agilent Technologies Inc.
    • 6.1.15 Sysmex Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS